Anadys Resumes Work With TLR7 Drug
This article was originally published in The Pink Sheet Daily
HCV candidate’s preclinical toxicity resolved, but investor focus is still mainly on polymerase inhibitor.
You may also be interested in...
Firm will send final study data on the cervical cancer vaccine to FDA in the first half of 2009, and approval could come six months later.
Phase III subject diagnosed with Wegener’s granulomatosis, a rare blood vessel inflammation.
Company signed a deal with Idera valued at $421 million, gaining two of its lead TLR9 candidates for oncology indications, excluding vaccines.